<SEC-DOCUMENT>0001958244-25-004303.txt : 20250904
<SEC-HEADER>0001958244-25-004303.hdr.sgml : 20250904
<ACCEPTANCE-DATETIME>20250904170446
ACCESSION NUMBER:		0001958244-25-004303
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250904
DATE AS OF CHANGE:		20250904

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		251294216

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BFI Co., LLC
		CENTRAL INDEX KEY:			0001601607
		ORGANIZATION NAME:           	
		EIN:				262105186
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		300 FRANK W. BURR BLVD., STE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		2013297300

	MAIL ADDRESS:	
		STREET 1:		300 FRANK W. BURR BLVD., STE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><ns2:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:ns2="http://www.sec.gov/edgar/ownership">
    <ns2:headerData>
        <ns2:submissionType>144</ns2:submissionType>
        <ns2:filerInfo>
            <ns2:filer>
                <ns2:filerCredentials>
                    <ns2:cik>0001601607</ns2:cik>
                    <ns2:ccc>XXXXXXXX</ns2:ccc>
                </ns2:filerCredentials>
            </ns2:filer>
            <ns2:liveTestFlag>LIVE</ns2:liveTestFlag>



        </ns2:filerInfo>
    </ns2:headerData>
    <ns2:formData>
        <ns2:issuerInfo>
            <ns2:issuerCik>0001069899</ns2:issuerCik>
            <ns2:issuerName>Phibro Animal Health Corporation</ns2:issuerName>
            <ns2:secFileNumber>001-36410</ns2:secFileNumber>
            <ns2:issuerAddress>
                <com:street1>Glenpointe Centre East, 3rd Floor</com:street1>
                <com:street2>300 Frank W. Burr Boulevard, Suite 21</com:street2>
                <com:city>Teaneck</com:city>
                <com:stateOrCountry>NJ</com:stateOrCountry>
                <com:zipCode>07666</com:zipCode>
            </ns2:issuerAddress>
            <ns2:issuerContactPhone>1-201-329-7300</ns2:issuerContactPhone>
            <ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>BFI Co. LLC</ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <ns2:relationshipsToIssuer>
                <ns2:relationshipToIssuer>10% Stockholder</ns2:relationshipToIssuer>
            </ns2:relationshipsToIssuer>
        </ns2:issuerInfo>
        <ns2:securitiesInformation>
            <ns2:securitiesClassTitle>Class A Common Stock</ns2:securitiesClassTitle>
            <ns2:brokerOrMarketmakerDetails>
                <ns2:name>Goldman Sachs &amp; Co. LLC</ns2:name>
                <ns2:address>
                    <com:street1>200 West Street</com:street1>
                    <com:city>New York</com:city>
                    <com:stateOrCountry>NY</com:stateOrCountry>
                    <com:zipCode>10282</com:zipCode>
                </ns2:address>
            </ns2:brokerOrMarketmakerDetails>
            <ns2:noOfUnitsSold>281600</ns2:noOfUnitsSold>
            <ns2:aggregateMarketValue>11002112</ns2:aggregateMarketValue>
            <ns2:noOfUnitsOutstanding>20367574</ns2:noOfUnitsOutstanding>
            <ns2:approxSaleDate>09/04/2025</ns2:approxSaleDate>
            <ns2:securitiesExchangeName>NASD</ns2:securitiesExchangeName>
        </ns2:securitiesInformation>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>Class A Common Stock</ns2:securitiesClassTitle>
            <ns2:acquiredDate>04/14/2014</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Private placement from issuer</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>Phibro Animal Health Corporation</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>281600</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>04/14/2014</ns2:paymentDate>
            <ns2:natureOfPayment>Exchange of Securities</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <ns2:remarks>The sales of shares set forth herein are made in connection with a selling plan dated 05/30/2025 that is intended to comply with Rule 10b5-1(c).</ns2:remarks>
        <ns2:noticeSignature>
            <ns2:noticeDate>09/04/2025</ns2:noticeDate>
            <ns2:planAdoptionDates>
                <ns2:planAdoptionDate>05/30/2025</ns2:planAdoptionDate>
            </ns2:planAdoptionDates>
            <ns2:signature>Goldman Sachs &amp; Co. LLC on behalf of Jack Bendheim</ns2:signature>
        </ns2:noticeSignature>
    </ns2:formData>
</ns2:edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
